Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results [Yahoo! Finance]
Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target raised by analysts at Barclays PLC from $26.00 to $31.00. They now have an "overweight" rating on the stock.